Edgewise Therapeutics, Inc.

This study looks at the long-term safety and effects of a drug called EDG-5506 (sevasemten) in adults and teenagers with Becker muscular dystrophy. About 260 people who have already taken part in earlier EDG-5506 studies can join. Researchers will track side effects and changes i…

This study tests a new medicine called EDG-7500 in 100 adults with hypertrophic cardiomyopathy, a condition where the heart muscle is too thick. The goal is to see if the drug is safe and can help reduce pressure inside the heart. Participants will receive either a single or mult…

This study tests an experimental drug called sevasemten (EDG-5506) in 244 adults and adolescents with Becker muscular dystrophy, a genetic condition that causes progressive muscle weakness. Participants receive either the drug or a placebo to see if it is safe and can improve mus…

This study tests an experimental drug called EDG-5506 (sevasemten) in 43 children aged 6 to 17 with Duchenne muscular dystrophy who have already received gene therapy. The goal is to see if the drug is safe and how it affects muscle health markers. Participants will first receive…

This study tests a drug called sevasemten in children aged 4-9 with Duchenne muscular dystrophy. The goal is to see if it is safe and how it affects muscle health. Some children get the drug, others get a placebo, and later all can receive the drug. The study is active but not cu…